Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with pancreatic cancer (confirmed by biopsy or cytology)
- You have not been treated with a PD-1 or PD-L1 inhibitor before
- You have at least one tumor that can be treated with radiation (not in the bone)
- Your overall health is good, with an ECOG score of 0 or 1 (you can do daily activities without help)
- You are willing to follow the study rules and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests a new treatment for stomach or colon cancer that has spread to the lining of the abdomen. It combines low-dose radiation with a type of immunotherapy called NIPS to help your body fight the cancer. The goal is to see if this combination can shrink the tumors and improve outcomes.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests whether giving low-dose radiation to liver tumors along with immunotherapy can help people with certain advanced cancers that have spread to the liver. It may improve how well the treatment works for people whose cancer has stopped responding to earlier treatments.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.